 | Up a level |
Chamuleau, Martine E D; Stenner, Frank; Chitu, Dana A; Novak, Urban; Minnema, Monique C; Geerts, Paul; Stevens, Wendy B C; Zenz, Thorsten; van Imhoff, Gustaaf W; Wu, Ka Lung; Demandt, Astrid M P; Kersten, Marie Jose; Terpstra, Wim E; Tick, Lidwine W; Deeren, Dries; Van Den Neste, Eric; Gregor, Michael; Veelken, Hendrik; Böhmer, Lara H; Caspar, Clemens B; ... (2023). R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. The Lancet. Haematology, 10(12), e966-e975. Elsevier 10.1016/S2352-3026(23)00279-X
Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; Gradowska, Patrycja; Biemond, Bart J; Spertini, Olivier; Vellenga, Edo; Griskevicius, Laimonas; Tick, Lidwine W; Jongen-Lavrencic, Mojca; van Marwijk Kooy, Marinus; Vekemans, Marie-Christiane; van der Velden, Walter J F M; Beverloo, Berna; Michaux, Lucienne; Graux, Carlos; Deeren, Dries; de Weerdt, Okke; van Esser, Joost W J; Bargetzi, Mario; ... (2021). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood advances, 5(4), pp. 1110-1121. American Society of Hematology 10.1182/bloodadvances.2020003855
